Vir Biotechnology, Inc. Common Stock
VIR US92764N1028
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 57% | -36% | -60% | -30% | 3% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Sato Vicki L |
5.84 USD |
22,000 Sold |
128,396 USD |
01/10/2025 | 01/10/2025 |
| Sato Vicki L |
4.99 USD |
22,000 Sold |
109,811 USD |
02/09/2025 | 02/09/2025 |
| Sato Vicki L |
4.99 USD |
22,000 Sold |
109,699 USD |
01/08/2025 | 01/08/2025 |
| Eisner Mark CMO |
5.47 USD |
3,586 Sold |
19,629 USD |
15/07/2025 | 17/07/2025 |
| Eisner Mark CMO |
5.47 USD |
6,796 Sold |
37,162 USD |
15/07/2025 | 15/07/2025 |
| Sato Vicki L |
5.10 USD |
22,000 Sold |
112,207 USD |
01/07/2025 | 01/07/2025 |
| Napolitano Janet |
5.05 USD |
3,200 Sold |
16,149 USD |
30/05/2025 | 02/06/2025 |
| Napolitano Janet |
5.05 USD |
3,200 Sold |
16,149 USD |
30/05/2025 | 02/06/2025 |
| De Backer Marianne CEO |
5.95 USD |
79,712 Sold |
474,239 USD |
03/04/2025 | 03/04/2025 |
| De Verneuil Vanina EX VP |
9.14 USD |
7,373 Sold |
67,402 USD |
26/02/2025 | 26/02/2025 |